Squarepoint Ops LLC Albireo Pharma, Inc. Transaction History

Squarepoint Ops LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$16.32 - $26.37 $262,115 - $423,528	16,061 New	16,061 $311,000
Q4 2021 Feb 14, 2022	SELL	$21.19 - $31.29 $542,485 - $801,055	-25,601 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$27.36 - $35.98 $222,819 - $293,021	8,144 Added 46.65%	25,601 $799,000
Q2 2021 Aug 16, 2021	BUY	$28.9 - $36.87 $300,531 - $383,411	10,399 Added 147.34%	17,457 $614,000
Q1 2021 May 17, 2021	BUY	$32.03 - $42.85 $226,067 - $302,435	7,058 New	7,058 $249,000
Q4 2020 Feb 16, 2021	SELL	$31.56 - $42.16 $298,178 - $398,327	-9,448 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$23.19 - $41.61 $8,394 - $15,062	-362 Reduced 3.69%	9,448 $315,000
Q2 2020 Aug 14, 2020	BUY	$14.82 - $29.92 $145,384 - $293,515	9,810 New	9,810 $260,000
Q1 2020 May 15, 2020	SELL	$11.67 - $27.23 $256,938 - $599,522	-22,017 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$16.92 - $28.96 $3,384 - $5,792	-200 Reduced 0.9%	22,017 $560,000
Q3 2019 Nov 14, 2019	BUY	$20.0 - $31.88 $294,020 - $468,667	14,701 Added 195.6%	22,217 $444,000
Q2 2019 Aug 14, 2019	BUY	$30.67 - $37.86 $230,515 - $284,555	7,516 New	7,516 $242,000

865

Ticker ALBO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,612,500
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.